Shanghai Medicilon Inc Working Capital to Net Assets Ratio
Shanghai Medicilon Inc working capital to net assets ratio. Shanghai Medicilon Inc (688202) has a Working Capital to Net Assets ratio of 32.6% as of June 2026. Working capital of CN¥653.23 Million (current assets of CN¥1.43 Billion minus current liabilities of CN¥778.75 Million) is measured against net assets of CN¥2.00 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check 688202 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Shanghai Medicilon Inc (2016–2025)
Working capital to net assets ratio of Shanghai Medicilon Inc from 2016 to 2025. This chart shows how Shanghai Medicilon Inc's Working Capital to Net Assets ratio has evolved across 10 annual periods from 2016 to 2025. As of June 2026, the ratio stands at 32.6%, reflecting working capital of CN¥653.23 Million against net assets of CN¥2.00 Billion CNY. See 688202 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Shanghai Medicilon Inc Working Capital to Net Assets Ratio by Year (2016–2025)
Shanghai Medicilon Inc working capital to net assets ratio by year from 2016 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Shanghai Medicilon Inc from 2016 to 2025, covering 10 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see balance sheet size of Shanghai Medicilon Inc.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 33.1% | CN¥640.37 Million | CN¥1.93 Billion | CN¥1.22 Billion | CN¥577.48 Million | ▼ -7.1 pp |
| 2024 | 40.2% | CN¥859.55 Million | CN¥2.14 Billion | CN¥1.44 Billion | CN¥576.15 Million | ▼ -7.2 pp |
| 2023 | 47.4% | CN¥1.19 Billion | CN¥2.51 Billion | CN¥1.88 Billion | CN¥686.36 Million | ▲ +19.0 pp |
| 2022 | 28.4% | CN¥455.59 Million | CN¥1.60 Billion | CN¥1.07 Billion | CN¥617.04 Million | ▼ -9.9 pp |
| 2021 | 38.3% | CN¥508.37 Million | CN¥1.33 Billion | CN¥892.04 Million | CN¥383.66 Million | ▼ -6.0 pp |
| 2020 | 44.3% | CN¥503.15 Million | CN¥1.14 Billion | CN¥699.29 Million | CN¥196.14 Million | ▼ -24.2 pp |
| 2019 | 68.5% | CN¥684.96 Million | CN¥1.00 Billion | CN¥799.02 Million | CN¥114.07 Million | ▲ +21.6 pp |
| 2018 | 46.9% | CN¥162.99 Million | CN¥347.89 Million | CN¥272.97 Million | CN¥109.99 Million | ▼ -8.3 pp |
| 2017 | 55.1% | CN¥158.43 Million | CN¥287.32 Million | CN¥243.49 Million | CN¥85.05 Million | ▼ -9.3 pp |
| 2016 | 64.5% | CN¥158.71 Million | CN¥246.09 Million | CN¥241.16 Million | CN¥82.45 Million | — |